Skip to main content
Fig. 2 | BMC Pediatrics

Fig. 2

From: Baloxavir safety and clinical and virologic outcomes in influenza virus-infected pediatric patients by age group: age-based pooled analysis of two pediatric studies conducted in Japan

Fig. 2

TTIA and TTRF by virus type/subtype, with/without PA/I38X-substituted viruses. Scatterplots of (a) time to alleviation of influenza illness and (b) time to resolution of fever, after treatment with baloxavir in patients with and without PA/138X-substituted viruses and with or without co-infection, by age and influenza virus type/subtype. For patients with influenza A, the subset of patients with paired sequencing at both baseline and post-treatment was included in this analysis. For patients with influenza B, patients in the ITTI population were included in this analysis. ITTI: intention-to-treat infected; PA/I38X: polymerase acidic protein variants at position I38; TTIA: time to illness alleviation; TTRF: time to resolution of fever

Back to article page

BMC Pediatrics

ISSN: 1471-2431

Contact us